Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins

EMBO Rep. 2024 Mar;25(3):951-970. doi: 10.1038/s44319-024-00063-3. Epub 2024 Jan 29.

Abstract

The exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). Recombinant antibodies genetically fused to this domain drive the degradation of membrane proteins that undergo constitutive internalisation and recycling, including the transferrin receptor and the human cytomegalovirus latency-associated protein US28. We term this approach PACTAC (PCSK9-Antibody Clearance-Targeting Chimeras).

Keywords: Human Cytomegalovirus; PACTAC; PCSK9; Targeted Protein Degradation.

MeSH terms

  • Humans
  • Membrane Proteins
  • Proprotein Convertase 9* / metabolism
  • Proprotein Convertases / metabolism
  • Receptors, LDL / metabolism
  • Serine Endopeptidases*

Substances

  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Serine Endopeptidases
  • Proprotein Convertases
  • Membrane Proteins
  • Receptors, LDL